Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies

Inclusion Criteria:

• Subjects will be eligible for enrollment in the study if they meet ONE criteria a, bor c in point 1 and ALL the criteria in points 2-9.

1. Subjects must meet ONE of the criteria a, b or c below:

2. For enrollment into Cohort A: Subjects with histologically confirmedadvanced or metastatic non-uveal/non-mucosal melanoma or merkel cellcarcinoma (MCPyV positive and negative) who are not amenable to surgicalcure and are candidates to receive single- or combined IOT alone (not toinclude cytotoxic chemotherapy) as first or second line treatment.

3. For enrollment into Cohort B: Subjects with histologically confirmedadvanced or metastatic clear cell Renal Cell Carcinoma or Renal CellCarcinoma with sarcomatoid features (regardless of subtype) as defined onpathologic examination by a component of clear cell or sarcomatoid, whoare not amenable to surgical cure and are candidates to receive single- orcombined IOT alone or IOT in combination with VEGFR-directed or tyrosinekinase inhibitor (not to include cytotoxic chemotherapy) as first orsecond line treatment

4. For enrollment into Cohort C: Subjects with histologically confirmedadvanced or metastatic non-small cell lung cancer withoutnon-smoker/driver mutations who are not amenable to surgical cure, and arecandidates to receive single- or combined IOT alone (not to includecytotoxic chemotherapy) as first or second line treatment as per thelabel/prescribing information at the physicians discretion. i. Patients with driver mutations that are expected to show significant benefitfrom first line checkpoint inhibiter treatment (such as KRAS G12C mutations)are eligible if all other I/E criteria are met Subjects must meet All of the criteria 2-9 below:

5. At least 1 RECIST 1.1-measurable. non-irradiated, non-osseous (unless there isan associated measurable soft-tissue component) lesion documented onintravenous (IV) contrast-enhanced CT or MRI (per RECIST criteria 1.1) prior tofirst zirconium Zr 89 crefmirlimab berdoxam administration.

6. Has an adequate amount of time between their prior treatment/procedure and the 1st administration of zirconium Zr 89 crefmirlimab berdoxam.

7. Eastern Cooperative Oncology Group (ECOG) performance status ≤2 and anticipatedsurvival of at least 6 months.

8. Meeting all clinical safety lab values per institution's SOC, or investigator'sdiscretion, for subjects receiving cancer treatment.

9. Male or female age ≥18 years.

10. Ability to understand the purposes and risks of the trial and has signed anInstitutional Review Board (IRB) approved informed consent form.

11. Willingness and ability to comply with all protocol required procedures.

12. For men and women of child-producing potential, use of effective double barriercontraceptive methods during the study, up to 30 days after the lastadministration of the investigational product.

Exclusion Criteria:

• Subjects will NOT be eligible for enrollment in the study if they meet ANY of thefollowing criteria:

1. Bone-only disease without a measurable soft tissue component on conventionalimaging (MRI, PET, CT).

2. Subjects with skin-only (cutaneous) lesions will be excluded from the tumorbiopsy assessment.

3. Serious nonmalignant disease, additional active malignant disease or conditionsthat in the opinion of the investigator and/or ImaginAb could compromiseprotocol objectives.

4. Subjects with splenic dysfunction or who are status post splenectomy.Post-splenectomy subjects who develop an accessory spleen with clinical andradiographic evidence of splenic function will be allowed with prior approvalfrom the Sponsor.

5. Corticosteroid therapy is prohibited if used for the treatment of inflammatoryor autoimmune conditions. Patients with adrenal insufficiency from priorsurgery or immunotherapy toxicity may be on standard chronic replacement dosesof hydrocortisone that also require sporadic use of stress doses of steroid .

6. Pregnant women or nursing mothers.